For the first time, people at risk of Alzheimer’s will have access to a new-generation drug to prevent the disease from occurring or slow it down. The “Generation” Study is recruiting thousands of people with copies of the APOE4 gene associated with Alzheimer’s for a trial of a new drug therapy. The drug is designed to reduce the activity of the BACE enzyme and reduce the further accumulation of beta amyloid in the brain.  (EXPRESS)